Venom Activated Assays Flashcards

1
Q

other name of reptilase time

A

Pefakit Reptilase Time
Pentapharm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

thrombin-like enzyme, batroxobin, isolated from the venom of ____________ that catalyzes the conversion of fibrinogen to fibrin

A

Bothrops atrox

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Factor associated to Reptilase Time

A

Facto II

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Obsolete name of Rusell Viper Venom Test

A

stypven time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

triggers coagulation at the level of factor X, was once used as an alternative to the PT

A

RVV Test

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

RVV test is from

A

Daboia russelii

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

early coagulation test developed by

A

A.J Quick

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Evaluates the function of Extrinsic & Common Pathway

A

PT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Major use of PT

A

monitor Warfarin anticoagulant therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Pre-surgery coagulation screening test

A

PT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Vitamin K antagonist that blocks the action of vitamin K

A

warfarin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

produced in liver

A

prothrombin II

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

PT REAGENT Contains a commercial preparation of _____________________________ substitutes for the tissue thromboplastin and calcium ions (Ca++) that are coagulation activators of the extrinsic pathway

A

Tissue Thromboplastin
calcium chloride

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Reference value of PT

A

3.2% CITRATED Plasma - 10-13 seconds

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Calculated value that allows standardization of prothrombin time reporting among different laboratories

A

INTERNATIONAL NORMALIZED RATIO (INR)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Assigned by the manufacturer to each reagent lot is used with the prothrombin time to calculate the INR

A

INTERNATIONAL SENSITIVITY INDEX (ISI)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

The extrinsic pathway is activated by ____________________ in the presence of calcium ions

A

Tissue Thromboplastin (F3)

18
Q

Proenzyme, is converted to the enzyme Xa, which in turn converts prothrombin to the enzyme thrombin

A

Factor X

18
Q

Proenzyme, is converted to the enzyme Xa, which in turn converts prothrombin to the enzyme thrombin

A

Factor X

19
Q

coagulation test used to monitor low-dose heparin therapy and to screen for function of the intrinsic and common pathways of hemostasis.

A

APTT

20
Q

reagent used in performing the APTT

A

Partial Thromboplastin

21
Q

Partial Thromboplastin Reagents

A

rabbit
bovine brain tissue
soybeans

22
Q

APTT activators

A

kaolin
silica

23
Q

Second reagent used in the test and is added to supply the ionized calcium required to activate prothrombin in the common pathway

A

calcium chloride

24
Q

APTT is performed combining citrated plasma with

A

partial thromboplastin and calcium chloride

25
Q

combined with partial thromboplastin for activation of factors in the intrinsic pathway begins

A

pre-warmed patient plasma

26
Q

APTT reference value

A

20-35 seconds

27
Q

Used to measure the availability of functional fibrinogen

A

TT

28
Q

TT is prolonged in case of

A

hypofibrogenemia
dysfibrogenemia
Presence of heparin | fibrin/fibrinogen products | thrombolytic agents (streptokiinase)

29
Q

Determines the rate of thrombin-induce cleavage of fibrinogen to fibrin monomers and the subsequent polymerization of hydrogen-bonded fibrin polymers

A

TT

30
Q

Mixing studies a.k.a

A

Circulating Anticoagulant Screen
Screening for Circulating Inhibitor

31
Q

Mixing studies a.k.a

A

Circulating Anticoagulant Screen
Screening for Circulating Inhibitor

32
Q

Mixing studies a.k.a

A

Circulating Anticoagulant Screen
Screening for Circulating Inhibitor

33
Q

assay is preceded by a thrombin time to detect therapeutic heparin or a direct thrombin inhibitor

A

Mixing study

34
Q

A mixing study is performed by measuring the APTT in the patient’s plasma, then mixing an equal volume of the patient’s plasma and normal pooled plasma (NPP) and repeating the APTT tests immediately and after 37 degC

A

true

35
Q

corrected after immediate mixing; not corrected after 2 hr of incubation

A

factor 8 inhibitor

36
Q

not corrected after immediate mixing; not corrected after 2 hr of incubation

A

Factor 5 (Leiden Inhibitor)
lupus anticoagulant

37
Q

used to identify specific coagulation factor deficiencies

A

substitution study
factor assay

38
Q

sample used in substitution study to identify deficiencies of blood coagulation

A

adsorbed plasma
aged serum
aged plasma

39
Q

decrease upon storage

A

F2
F8
Labile (F5)

40
Q

amount of F2 present in fresh serum

A

<20%

41
Q

F2 consumed during coagulation

A

80%